LA JOLLA, Calif., April 23, 2013 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCBB:INNV) today announced that the European Patent Office ("EPO") has issued an official decision to grant the company's patent entitled, "Process for Preparing an Anti-Microbial Fraction from Juglans Regia."
The company has been granted patents in the U.S. and in Morocco, where the extract originated. The European patents, when issued, will give a wide and strong patent protection. The matter of the patent covers water-based extraction and anti-microbial activity of an extract of J. Regia.
J. Regia extracts are currently marketed in multiple North African countries and Europe under the product line Souakine by the French company, Cosmetique Medicale Paris.
Dr. Bassam Damaj, Ph.D., Chief Executive Officer of Innovus Pharma, commented, "We are very pleased to receive this important patent allowance in Europe for J. Regia extracts as it puts the company in a strong position to initiate our commercial license with Cosmetique Medicale Paris and extend the license to additional territories."
Innovus Pharma, headquartered in La Jolla, is a global healthcare company that delivers innovative and uniquely presented and packaged health solutions through its prescription medicines and consumer and health products.
Innovus is an emerging pharmaceutical company that develops, in-licenses, acquires and markets proprietary pharmaceutical products. Innovus has a robust pipeline that will be positioned and for unique packaging and presentation, especially for ease of use and patient compliance, with a focus on dermatology, autoimmune disease, sexual dysfunction, and respiratory disease.
For more information, go to: www.innovuspharma.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may be considered to be "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that may individually or mutually impact the matters described in this release for a variety of reasons, many of which are outside the control of Innovus Pharma. These risks and uncertainties include, but are not limited to Innovus Pharma's ability to negotiate the definitive agreements for the acquisition of the line of prescription products in dermatitis on terms and conditions satisfactory to it, Innovus Pharma's ability to raise sufficient capital to fund its operations and growth strategy in the long term, Innovus Pharma's ability to achieve its development, regulatory, commercialization and financial goals for its existing products, its ability to acquire additional products, and its ability to achieve development, regulatory, commercialization and financial goals for such additional products. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K and other filings made with the SEC. Copies of these reports are available from the SEC's website or the "Investors" section of Innovus Pharma's website at innovuspharma.com.
Innovus Pharma Contact: Kevin Holmes Chesapeake Group T: 410-825-3930